ATXS
Price
$4.23
Change
-$0.17 (-3.86%)
Updated
May 9 closing price
Capitalization
238.72M
2 days until earnings call
CELC
Price
$10.15
Change
-$0.38 (-3.61%)
Updated
May 9 closing price
Capitalization
384.07M
4 days until earnings call
Ad is loading...

ATXS vs CELC

Header iconATXS vs CELC Comparison
Open Charts ATXS vs CELCBanner chart's image
Astria Therapeutics
Price$4.23
Change-$0.17 (-3.86%)
Volume$470.95K
Capitalization238.72M
Celcuity
Price$10.15
Change-$0.38 (-3.61%)
Volume$141.34K
Capitalization384.07M
ATXS vs CELC Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. CELC commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and CELC is a Hold.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (ATXS: $4.23 vs. CELC: $10.15)
Brand notoriety: ATXS and CELC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 113% vs. CELC: 54%
Market capitalization -- ATXS: $238.72M vs. CELC: $384.07M
ATXS [@Biotechnology] is valued at $238.72M. CELC’s [@Biotechnology] market capitalization is $384.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileCELC’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • CELC’s FA Score: 0 green, 5 red.
According to our system of comparison, CELC is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 3 TA indicator(s) are bullish while CELC’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 3 bullish, 5 bearish.
  • CELC’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CELC is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а -21.08% price change this week, while CELC (@Biotechnology) price change was -6.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.25%. For the same industry, the average monthly price growth was +9.40%, and the average quarterly price growth was -13.49%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

CELC is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-6.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($384M) has a higher market cap than ATXS($239M). CELC YTD gains are higher at: -22.460 vs. ATXS (-52.685). CELC has higher annual earnings (EBITDA): -85.45M vs. ATXS (-111.56M). ATXS has more cash in the bank: 328M vs. CELC (264M). ATXS has less debt than CELC: ATXS (5.35M) vs CELC (97.2M). ATXS (0) and CELC (0) have equivalent revenues.
ATXSCELCATXS / CELC
Capitalization239M384M62%
EBITDA-111.56M-85.45M131%
Gain YTD-52.685-22.460235%
P/E RatioN/AN/A-
Revenue00-
Total Cash328M264M124%
Total Debt5.35M97.2M6%
FUNDAMENTALS RATINGS
ATXS vs CELC: Fundamental Ratings
ATXS
CELC
OUTLOOK RATING
1..100
2275
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
45
Fair valued
PROFIT vs RISK RATING
1..100
10079
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
6458
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELC's Valuation (45) in the Miscellaneous Commercial Services industry is in the same range as ATXS (61) in the Biotechnology industry. This means that CELC’s stock grew similarly to ATXS’s over the last 12 months.

CELC's Profit vs Risk Rating (79) in the Miscellaneous Commercial Services industry is in the same range as ATXS (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as CELC (98) in the Miscellaneous Commercial Services industry. This means that ATXS’s stock grew similarly to CELC’s over the last 12 months.

CELC's Price Growth Rating (58) in the Miscellaneous Commercial Services industry is in the same range as ATXS (64) in the Biotechnology industry. This means that CELC’s stock grew similarly to ATXS’s over the last 12 months.

CELC's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as ATXS (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSCELC
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA298.2613.44
+4.72%
Tesla
GME27.540.76
+2.84%
GameStop Corp
AAPL198.531.04
+0.53%
Apple
SPY564.34-0.72
-0.13%
SPDR® S&P 500® ETF
BTC.X102970.850000-270.609380
-0.26%
Bitcoin cryptocurrency

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-3.86%
KYMR - ATXS
56%
Loosely correlated
-2.27%
TRDA - ATXS
54%
Loosely correlated
-2.78%
APGE - ATXS
53%
Loosely correlated
-1.38%
DNLI - ATXS
53%
Loosely correlated
-0.42%
XENE - ATXS
52%
Loosely correlated
-1.46%
More

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with PRME. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-3.61%
PRME - CELC
46%
Loosely correlated
-1.52%
ATXS - CELC
45%
Loosely correlated
-3.86%
CLDX - CELC
45%
Loosely correlated
-6.10%
ABOS - CELC
43%
Loosely correlated
-1.99%
NUVB - CELC
42%
Loosely correlated
-0.48%
More